UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Design and optimization of highly-selective fungal CYP51 inhibitors

Bioorganic & medicinal chemistry letters, 2014-08, Vol.24 (15), p.3455-3458

2014

Volltextzugriff (PDF)

VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans

Journal of antimicrobial chemotherapy, 2018-01, Vol.73 (1), p.151-155

2018

Volltextzugriff (PDF)

Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors

Bioorganic & medicinal chemistry letters, 2014-06, Vol.24 (11), p.2444-2447

2014

Volltextzugriff (PDF)

Development of Highly Selective Pyrimidine-Based Aldosterone Synthase (CYP11B2) Inhibitors

ACS medicinal chemistry letters, 2019-07, Vol.10 (7), p.1056-1060

2019

Volltextzugriff (PDF)

Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis

The Journal of biological chemistry, 2017-04, Vol.292 (16), p.6728-6743

2017

Volltextzugriff (PDF)

A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis

Clinical infectious diseases, 2021-10, Vol.73 (7), p.e1518-e1524

2021

Volltextzugriff (PDF)

A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis

American journal of obstetrics and gynecology, 2018-06, Vol.218 (6), p.624.e1-624.e9

2018

Volltextzugriff (PDF)

Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors

Bioorganic & medicinal chemistry letters, 2017-08, Vol.27 (15), p.3243-3248

2017

Volltextzugriff (PDF)

Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus

Journal of antimicrobial chemotherapy, 2018-02, Vol.73 (2), p.404-408

2018

Volltextzugriff (PDF)

The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris

Antimicrobial agents and chemotherapy, 2019-03, Vol.63 (3)

2019

Volltextzugriff (PDF)

In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans

Antimicrobial agents and chemotherapy, 2019-06, Vol.63 (6)

2019

Volltextzugriff (PDF)

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii

Antimicrobial agents and chemotherapy, 2016-04, Vol.60 (4), p.2528-2531

2016

Volltextzugriff (PDF)

Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161

Antimicrobial agents and chemotherapy, 2019-10, Vol.63 (10)

2019

Volltextzugriff (PDF)

The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme

Antimicrobial agents and chemotherapy, 2016-08, Vol.60 (8), p.4530-4538

2016

Volltextzugriff (PDF)

The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis

Antimicrobial agents and chemotherapy, 2018-04, Vol.62 (4)

2018

Volltextzugriff (PDF)

VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection

Antimicrobial agents and chemotherapy, 2015-12, Vol.59 (12), p.7815-7817

2015

Volltextzugriff (PDF)

Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection

Antimicrobial agents and chemotherapy, 2017-09, Vol.61 (9)

2017

Volltextzugriff (PDF)

VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice

Journal of antimicrobial chemotherapy, 2018-08, Vol.73 (8), p.2089-2094

2018

Volltextzugriff (PDF)

In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy

Antimicrobial agents and chemotherapy, 2018-11, Vol.62 (11)

2018

Volltextzugriff (PDF)

Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs

Antimicrobial agents and chemotherapy, 2017-05, Vol.61 (5)

2017

Volltextzugriff (PDF)

Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs

Medical mycology (Oxford), 2017-06, Vol.55 (4), p.453-456

2017

Volltextzugriff (PDF)

The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis

Antimicrobial agents and chemotherapy, 2018-09, Vol.62 (9)

2018

Volltextzugriff (PDF)

Effects of Pyridoxamine in Combined Phase 2 Studies of Patients with Type 1 and Type 2 Diabetes and Overt Nephropathy

American journal of nephrology, 2007-10, Vol.27 (6), p.605-614

2007

Volltextzugriff (PDF)

Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models

Antimicrobial agents and chemotherapy, 2015-12, Vol.59 (12), p.7249-7254

2015

Volltextzugriff (PDF)

The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51

Antimicrobial agents and chemotherapy, 2017-07, Vol.61 (7)

2017

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Pharmacology & Pharmacy
(21)
Microbiology
(18)
Animals
(13)
Pyridines
(13)
Tetrazoles
(13)
Antifungal Agents - Pharmacology
(12)
Pyridines - Pharmacology
(12)
Tetrazoles - Pharmacology
(12)
Antifungal Agents
(11)
Experimental Therapeutics
(11)
Humans
(11)
Microbial Sensitivity Tests
(10)
Fluconazole - Pharmacology
(8)
Sterol 14-Demethylase - Metabolism
(8)
14-Alpha Demethylase Inhibitors
(7)
Mice
(7)
Male
(6)
14-Alpha Demethylase Inhibitors - Pharmacology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Design and optimization of highly-selective fungal CYP51 inhibitors

VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans

Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors

Development of Highly Selective Pyrimidine-Based Aldosterone Synthase (CYP11B2) Inhibitors

Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis

A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis

A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis

Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors

Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus

The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris

In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii

Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161

The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme

The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis

VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection

Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection

VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice

In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy

Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs

Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs

The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis

Effects of Pyridoxamine in Combined Phase 2 Studies of Patients with Type 1 and Type 2 Diabetes and Overt Nephropathy

Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models

The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51

Suchergebnisse filtern